Test drug HS-10382 for chronic myeloid leukemia after prior treatment
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase study tests HS-10382 in adults with chronic myeloid leukemia (CML) whose leukemia is resistant to or not tolerated of standard pills. It aims to see if the drug can control CML when earlier treatment hasn’t worked for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 74 years old and can sign consent
- You have CML in the chronic phase or accelerated/blast phase, with the Ph chromosome or BCR-ABL1 fusion found on tests
- Your CML is resistant to or you can’t tolerate prior CML pills called TKIs
- Your overall function is good enough (ECOG 0 to 2) and you have life expectancy of at least 12 weeks
- You must use effective birth control during the study (and breastfeeding is not allowed during and for 6 months after)
- Your heart, pancreas, and other organ health must meet safety limits (including an ECG without concerning QT problems)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (HS-10382 plus another drug) for people with chronic myeloid leukemia (CML) whose current treatments have stopped working or caused side effects. It may help if you have a certain type of CML that is not controlled by previous therapies.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This trial tests a new targeted therapy pill (TGRX-678) for adults with chronic-phase CML who no longer benefit from or cannot tolerate at least three other targeted therapies. The goal is to see if this drug can control the leukemia better.
This trial tests a new daily tablet (TQB3911) for people with chronic myeloid leukemia (CML) whose current targeted therapy (TKI) has stopped working or caused side effects. The goal is to see if this new drug is safe and can better control the leukemia.
This study tests a new daily pill called TGRX-678 for people with chronic-phase CML who have not responded well to or cannot tolerate other CML treatments. It aims to see if the drug is safe and if it can help control the leukemia.
Hear when a new CML, Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.